Marksans Q1 FY27: consolidated PAT jumps 174% YoY to ₹159 Cr as NPM expands to ~19%
PAT +173.89% YoY · revenue +35.61% · margins expanding
₹840.8 Cr
+35.61% YoY
₹159.41 Cr
+173.89% YoY
18.4%
+9.1pp YoY
₹3.47
Marksans Pharma's consolidated Q1 FY27 (quarter ended 30 June 2026) revenue came in at ₹840.80 Cr, up 35.6% YoY from ₹619.99 Cr but down 1.8% QoQ from ₹856.11 Cr. Consolidated PAT rose to ₹159.41 Cr, up 173.9% YoY from ₹58.20 Cr and 7.0% QoQ from ₹149.03 Cr — ₹157.17 Cr attributable to owners and ₹2.24 Cr to non-controlling interests (mainly the 60%-held Nova Pharmaceuticals Australasia). Net profit margin expanded to 18.96%, from 9.30% a year ago and 16.72% last quarter; basic EPS was ₹3.47 against ₹1.29 a year ago. Standalone (India-only) revenue was ₹321.19 Cr with PAT of ₹69.04 Cr — materially smaller than the group figure, which is expected since standalone excludes the UK, US and other overseas subsidiaries, not a sign the two numbers disagree.
Q1 FY-2027 vs prior quarters
The scale of the YoY PAT jump is partly a low-base effect: the year-ago quarter (June 2025) had itself seen consolidated net profit decline versus its own prior year, per contemporaneous market reports, so 173.9% growth overstates the underlying run-rate even though no exceptional item is disclosed in this statement. The more telling number is the 7.0% QoQ profit growth against a 1.8% QoQ revenue dip — margin expansion, not volume, drove the sequential improvement. Estimated EBITDA margin (PBT adjusted for other income, finance costs and depreciation) works out to ~25.3% of revenue, well above management's guided 20-21% band for FY27, helped by contained employee and material costs as a share of revenue and a ₹25.40 Cr other-income line that included a ₹12.00 Cr net forex gain versus a forex loss in the year-ago quarter.
The stock went into the print at ₹303.55, up 12% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters.
Marksans Pharma provided an optimistic outlook, reaffirming its target of INR4,000 crores in revenue by FY28 and a roadmap to double revenue in 3-5 years. The company expects EBITDA margins to remain in the 20-21% range for FY27 despite potential raw material cost inflation, forecasting a 15-20% top-line growth for FY2
— This quarter: beat
Against management's FY27 guidance — 15-20% topline growth, 20-21% EBITDA margins, both reaffirmed at the May 2026 concall — the quarter runs ahead on both counts, though it is one quarter against a full-year target. We found no analyst consensus estimates or brokerage previews for this specific print in a web search, so the print's standing versus street is unknown; no management press release accompanying the filing was available to cross-check against the auditor-reviewed statement. During the quarter the company completed the acquisition of Netherlands-based QliniQ B.V. (EUR 7.5 million), now consolidated and contributing to the topline; separately, it signed and — after quarter-end, on 20 July 2026 — completed the acquisition of Germany's ABCnow GmbH (EUR 1.1 million), a frontend sales and distribution platform, consistent with management's stated M&A focus on distribution platforms in diversified geographies. Both statements carry unmodified limited-review opinions from MSKA & Associates.
W1
Whether the ~25.3% estimated EBITDA margin (vs management's guided 20-21% FY27 band) holds as raw-material cost inflation flows through, per management's own stated risk
W2
ABCnow GmbH (Germany) integration — deal completed 20 July 2026, post quarter-end — watch its contribution to Q2 FY27 revenue and opex
W3
Full-year revenue trajectory against the 15-20% FY27 growth guidance, given Q1's 35.6% YoY print benefits from a soft year-ago (June 2025) base that rolls off in H2
Native-text PDF but line-item/figure alignment needed cross-verification via Total Income − Total Expenses = PBT and PBT − Tax = PAT (both checks pass exactly); PAT figure used is total PAT (owners ₹157.17 Cr + NCI ₹2.24 Cr = ₹159.41 Cr) to match our records' convention; no exceptional items disclosed; converted from ₹ million to ₹ Crore.
35% Growth, 15% Guidance: A Record Quarter on Borrowed Margins
Marksans delivered record profit (+173.9% PAT) on a 35.6% revenue beat, yet held FY27 guidance at just 15-20% growth. The call reveals why: the quarter is propped by temporary margin drivers—while Europe's 53% organic breakout is the real story worth owning.
₹840.8 Cr
+35.6% YoY
₹159.4 Cr
+173.9% YoY
59.1%
vs 55-56% sustainable
₹213 Cr
Highest-ever; +112.8% YoY
Why a 35% beat didn't move guidance
Q1 looks exceptional on paper: revenue +35.6%, PAT +173.9%, EBITDA a record ₹213 crores at 25.3% margin. Yet management walked off the call with FY27 guidance unchanged at 15-20% revenue growth. That gap—between a quarter that crushed and a full-year forecast that didn't budge—is the quarter's real message. On the call, management was transparent about why: the reported beat leans on temporary drivers. Low-cost inventory is being depleted, FX is favorable but reversible, and product mix shifted favorably. Once these normalize, gross margin will compress from 59.1% to the 55-56% sustainable range management guides. That's 300-400 basis points of downside sitting in the headline numbers. Management flagged it candidly. The question is whether Q2-Q4 will confirm it.
Organic vs. tailwind: breaking down the beat
The real win is organic revenue: 35%+ growth excluding M&A, across all geographies. Europe's 53.1% organic growth ex-QliniQ is the standout. But the PAT surge of 173.9% is an artifact of temporary margin expansion. Once inventory normalizes and FX reverses, that margin compresses 300-400 bps. Management knew this on the call and said it plainly—which is why they held guidance despite being massively pressed to raise it.
Management claims: graded against the numbers
"Highest-ever quarterly EBITDA of ₹213 crores"
"QliniQ contributed ₹44 Cr Q1; organic Europe grew 53.1% ex-QliniQ"
"Gross margin sustainable at 55-56% range"
"North America ₹377 Cr at 45% of total; 15.1% growth"
"Will hit ₹4,000 crores by FY28"
The last claim needs scrutiny. At current run-rate, Marksans is tracking ~₹3,364 crores annualized from Q1. Hitting ₹4,000 Cr by FY28 (one year out) requires 19% CAGR—a step above their midpoint 17.5% FY27 guidance. Management reaffirmed the ₹4,000 Cr target but declined to raise near-term guidance, which suggests either hidden visibility into H2 acceleration, or the target is aspirational. Verdict: plausible but not committed. Europe M&A and the 3-5 year doubling vision are real, but contingent on execution and macro cooperation.
What shifted on this call
Europe M&A schedule
QliniQ (Netherlands) closed; ABCnow (Germany) consolidating; Ireland entity live
Upgrade (pulled forward 1 year)
M&A activity expected in 2027
FY27 revenue growth
Reaffirmed despite 35.6% Q1
Unchanged (cautious)
15-20%
Gross margin guidance
Explicitly 55-56% sustainable; flagged 59.1% temporary
Clarification (signaled risk)
Implicit in 20-21% EBITDA target
How the street is positioned
The stock's reaction post-result maps the analyst debate: day-1 disappointment, followed by re-rating once the margin drivers became clear.
-2.94%
Market punished guidance hold
+6.03%
Bounce began; Europe story re-rated
+4.61%
Bounce held; institutional conviction
At current levels (₹327 as of Aug 19), the stock sits 5.3% below its all-time high of ₹345.25, yet is up 111% from the 52-week low. RSI of 81.5 signals overbought technicals, but volume is increasing—no sign of distribution yet. The initial -2.94% reflects investor frustration that management didn't raise FY27 guidance despite the beat. By day 3, the bounce began as the market digested management's transparency on gross margin drivers and the 53%+ organic growth in Europe. The bounce held through day 5, suggesting institutional conviction that the underlying story (Europe breakout, organic momentum, long-term doubling) justifies the valuation despite near-term margin headwinds.
17.47%
+71 bps QoQ (net buying)
6.19%
-38 bps QoQ (trimming)
43.87%
Stable; no dilution
Foreign institutions are adding—a net positive signal on a quality, high-growth story. Domestic institutions trimmed marginally, possibly profit-taking or value-rotation bias. Promoter stake is steady at 43.87%; no insider selling near the highs. Bulk trades show Microcurves Trading as simultaneous buyer/seller at ₹313.24/₹313.40—a neutral crossing, not a red flag. Overall, institutional posture is net supportive of the long-term narrative.
The bull-bear ledger
Bull: Organic revenue growth 35%+ across all geographies; Europe organic momentum at 53% is a genuine step-change
Bull: Europe M&A (QliniQ + ABCnow) already closed vs. prior 2027 guidance; ₹180 Cr full-year Europe target is credible
Bull: Management disciplined and transparent; flagged margin compression risk, avoided over-promising on FY27
Bull: Long-term targets (₹4,000 Cr FY28, doubling in 5 years) have credible mechanisms (M&A, geographic expansion, manufacturing ramp)
Bull: Net cash ₹1,031 Cr (first time >₹1,000 Cr); ammunition for further M&A and geographic expansion
Bear: Gross margin 59.1% inflated by low-cost inventory depletion (finite), FX tailwind (reversible), and favorable mix; 55-56% sustainable implies 300-400 bps compression
Bear: 35.6% Q1 growth vs 15-20% FY27 guidance implies sharp deceleration in H2 or Q1 is propped by one-time benefits; credibility risk if H2 beats materially
Bear: Working capital improvement (132 days vs 159 days) driven by inventory, not structural process gains; will normalize as inventory rebuilds
Bear: USFDA plant inspection timing unpredictable; 45% of revenue (North America) exposed to regulatory risk
Bear: Macro headwinds (war, freight inflation, geopolitical volatility) cited as reason for guidance caution; non-Western markets explicitly struggling
Risks, ranked by severity for a holder
Gross margin compression (59.1% → 55-56% in H2/FY28)
High300-400 bps downside when low-cost inventory depletes and FX normalizes. Reported PAT ₹159.4 Cr includes ₹11-18 Cr from temporary drivers. Adjusted PAT closer to ₹141-148 Cr. This is the earnings quality risk that matters most.
FY27 guidance credibility (15-20% vs Q1's 35.6% growth)
HighIf H2 beats 15-20% by a wide margin, it signals either poor management visibility or intentional sandbagging for risk cover. Credibility erosion affects future re-ratings.
Europe M&A integration (QliniQ + ABCnow execution)
MediumFresh acquisitions; synergy realization and revenue ramp uncertain. Ireland entity needs product/distribution licenses; no FY27 revenue expected. Revenue miss (vs ₹150-175 Cr QliniQ, ₹180 Cr Europe targets) breaks growth narrative.
USFDA regulatory compliance and inspection timing
MediumUnpredictable plant inspection cycles; 45% of revenue (North America ₹377 Cr) at risk. One facility audited <12 months ago but can recur anytime. Inspection failure could force shutdowns.
Macro headwinds (geopolitical, freight, raw materials)
MediumWar, vessel disruptions, fuel inflation, consumer affordability pressure explicitly cited by management. Rest of World (₹20 Cr) flagged as struggling. Offset by geographic diversification, but real near-term pressure.
The debate
What to watch next
1 · Q2 FY27: Organic revenue and margin normalization
Will organic (ex-QliniQ) revenue growth moderate to the 15-20% FY27 guidance range? Will gross margin compress toward 55-56% sustainable, confirming management's thesis? If Q2 gross margin is still 58%+, inventory depletion is slower than expected (positive signal). If 54-55%, compression is faster (negative). The Q2 organic run-rate will show if the 15-20% FY27 guidance is tight or loose.
2 · Europe acquisition integration: QliniQ and ABCnow ramp
Can QliniQ hit its full-year ₹150-175 Cr target (₹44 Cr Q1 implies ₹40-45 Cr quarterly run-rate, which is in line)? When does ABCnow consolidation revenue start (expected Q2)? Does Ireland secure licenses and ramp in FY28 as guided? These acquisitions are the linchpin of the ₹180 Cr Europe full-year target and the ₹1,000 Cr 5-year vision. Revenue miss = growth narrative breaks.
3 · USFDA regulatory clarity
No predictable timeline for the next plant inspection, but regulatory status (or an announcement of an audit) could trigger sharp repricing. 45% of revenue (North America ₹377 Cr) hangs on compliance. Any inspection notice should prompt immediate re-read of the regulatory risk.
Marksans delivered a technically exceptional Q1 in revenue, profit, and EBITDA—but the quarter sits on borrowed margin and fresh M&A accounting. The underlying business (35%+ organic growth, Europe 53%+ organic, robust cash generation) is sound. Management's refusal to upgrade FY27 guidance was the right call—it signals integrity and flags margin compression ahead. The market's day-1 disappointment gave way to a +6% rebound by day 3, reflecting re-rating of the underlying strength once the margin story became clear. This is not a spectacular momentum buy; it's a steady compounder with near-term margin headwinds and long-term geographic upside.
Rating: Hold, with upside catalyst if H2 beats 15-20% by more than temporary factors would explain. The single number to track: Q2-Q3 organic PAT after margin normalization—that will tell whether ₹159 Cr is a peak or a credible baseline for the 3-5 year doubling target.
North America momentum carries into Q1; 15–20% FY27 growth on track
Management guidance for 15–20% FY27 revenue growth and 20–21% EBITDA margin sets up a steady Q1 against a backdrop of strong Q4 FY26, two acquisitions (QliniQ, ABCnow), and a bullish Street on the ₹4,000 Cr FY28 roadmap.
The Setup: FY27 at the inflection point
Marksans enters Q1 FY27 against a strong FY26 print — revenue ₹3,033 Cr (a record), EBITDA ₹601 Cr at 20.4% margin, and PAT ₹420 Cr. Management reaffirmed 15–20% FY27 revenue growth with EBITDA margin guidance of 20–21%, anchoring to an ambitious ₹4,000 Cr FY28 target. The Street priced this in: consensus is Strong Buy at ₹266–302 target price, with current stock at ₹271.45 slightly above the midpoint.
North America is the key watch — it crossed ₹1,533 Cr in FY26, a 30%+ growth zone. Q1 FY26 (June 2025) saw North America revenue of ₹327.6 Cr (30.6% YoY growth), a taste of sustained momentum. If that trajectory holds, Q1 FY27 could see North America in the ₹360–380 Cr band, underpinning overall guidance.
~₹720–750 Cr
15–20% FY27 growth; Q1 seasonally softer than full-year run-rate
~20–21%
Guided range; FY26 was 20.4%; margin resilience key to ₹4,000 Cr target
15–20% growth expected
FY26 PAT ₹420 Cr; Q1 typically 20–25% of annual (before seasonal peaks)
A strong Q1 looks like: revenue in the ₹745–770 Cr range, EBITDA margin holding above 20%, and North America contribution >50% of the total. A weak Q1 would flag: revenue <₹710 Cr, margin compression below 19.5%, or North America growth stalling <15% YoY.
On track? The FY27 roadmap
Marksans is squarely on its stated path. FY26 delivered record revenue and profit; management has published clear 15–20% FY27 growth and the ₹4,000 Cr FY28 milestone. Acquisitions of QliniQ (€7.5M, Netherlands, ₹9.35 Cr revenue, €1.01M PAT in prior year) and ABCnow (€892K, Germany, pharmaceutical distribution) close the capability gap in EU/Germany — a strategic infill for the ₹4,000 Cr roadmap. Both are accretive; neither is transformative, but both expand the regulated-market footprint.
The risk: Q1 FY27 could be a barometer of execution. Seasonal softness is normal (Q1 is typically 18–22% of annual revenue), but if North America loses momentum or margin pressure emerges earlier than guided, the full-year 15–20% target could come into question.
What the Street says
Since last quarter: Corporate actions & filings
1 · Acquisitions closed (QliniQ, ABCnow)
QliniQ (Netherlands, €7.5M, June 16) and ABCnow (Germany, €892K, July 20) are now consolidated. QliniQ contributed €9.35 Cr revenue and €1.01 M PAT pre-acquisition; will begin accretion in Q1 FY27 P&L. Strategy is clear: widen regulated-market footprint ahead of ₹4,000 Cr FY28 run-rate.
2 · FY26 Annual Report & AGM notice (August 4)
34th AGM scheduled August 27, 2026 (virtual). BRSR filed. No material red flags in corporate governance; routine compliance. Record date for final dividend ₹0.90 (90% payout) set for August 20.
3 · Ownership: FII uptick
FII holding rose to 17.47% in Q1 FY27 (vs. 16.76% Q4 FY26), a +71bp increase. Promoter steady at 43.87%. Modest foreign inflow post-AGM guide suggests Street confidence in the ₹4,000 Cr roadmap.
4 · Insider trading window closed (June 26)
Standard pre-results closure; no anomalous insider activity reported. Clean slate into result.
The watchlist — result day pivots
1 · North America revenue & growth
Is North America >50% of total Q1 revenue? Growth >15% YoY? Anything below that, or a miss on commentary (customer wins, approvals), flags Q1 as soft. At ₹1,533 Cr in FY26, MARKSANS is gun-shy about growth slowdowns.
2 · EBITDA margin print vs. 20–21% guide
FY26 was 20.4%. If Q1 comes in <19.5%, or if management cuts FY27 margin guidance, it signals cost inflation or mix pressure — a red flag for the ₹4,000 Cr roadmap assumption. Margin is non-negotiable in the consensus case.
3 · FY27 guidance reaffirmation & FY28 color
Will management reiterate 15–20% FY27 growth and 20–21% EBITDA? Any narrowing, pushback, or delay in ₹4,000 Cr FY28 timeline (currently 'one year of approvals/filings') will de-rate. The market has priced in confidence; a shrug is a sell signal.
Marksans' Q1 FY27 is a straight read: can the company deliver 15–20% revenue growth, hold EBITDA margin at 20–21%, and keep North America momentum intact? It's been on target; the market has priced 'on-track' at ₹271 today. A beat on revenue and margin holds the bull case. A miss — especially on margins — tips the narrative toward re-rating. With the ₹4,000 Cr FY28 target the north star, Q1 is a make-or-break read of execution. Consensus Strong Buy holds on guidance confirmation and steady Q1 print; watch for any equivocation on the outer-year roadmap.
Record quarter masks FY27 caution; Europe breakout offsets guidance gap
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Hit ₹4,000 Cr FY28 target reaffirmed, FY27 15-20% guidance reaffirmed. Europe M&A on track. No prior misses called out.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Exceptional Q1 execution (₹159 Cr PAT, 35.6% growth) and Europe breakout offset by management's refusal to raise FY27 guidance (15-20% growth) and acknowledgment that 59% gross margins are temporary. Key risk: whether Q2-Q4 growth moderates sharply or current momentum sustains; current guidance implies significant deceleration.
₹840.8 Cr
Revenue · +35.6% YoY₹159.4 Cr
Reported PAT · +173.9% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Highest-ever quarterly EBITDA of ₹213 crores
METEBITDA ₹213 Cr at 25.3% margin, up 112.8% YoY from ₹100.1 Cr
QliniQ contributed ₹44 crores in Q1; organic Europe grew 53.1% ex-QliniQ
METTotal Europe revenue ₹356 Cr (74.7% YoY); ₹356 - ₹44 = ₹312 Cr organic; implies ₹312 / baseline ≈ 53% YoY growth
Gross margin sustainable at 55-56% range
METCurrent 59.1% inflated by favorable mix, depleting low-cost inventory, and FX tailwind; management acknowledges temporary drivers
US market contribution 45% of revenue with 15.1% growth, softer summer seasonality
METNorth America ₹377 Cr at 15.1% YoY; 45% of ₹840.8 total confirmed
Will hit ₹4,000 crores within next two years
OVERSTATEDCurrently ₹841 Cr annualized implies ₹3,364 Cr run-rate; reaching ₹4,000 in FY28 requires ~19% CAGR from FY27
Earnings quality
What changed since the last call
Europe M&A momentum accelerated
UpgradePrior guidance said 'M&A expected in 2027'; already closed QliniQ (Netherlands) and ABCnow (Germany) in 2026. Europe target ₹180 Cr FY27 vs implicit lower base in prior guidance.
FY27 guidance maintained despite beat
NeutralPrior 15-20% revenue growth and 20-21% EBITDA margin reaffirmed. Management cited 'geopolitical volatility' as reason to hold despite 35.6% Q1 growth. Implies caution on sustainability.
Gross margin floor clarified
Downgrade55-56% flagged as sustainable level vs current 59.1%, acknowledging inventory depletion and FX tailwind are temporary. Implies 300-400 bps margin contraction risk if current drivers reverse.
The Q&A
Analysts pressed on gross margin sustainability, guidance conservatism, capex allocation, and India manufacturing plans. Management held firm on guidance despite Q1 beat, framing caution as prudent vs macro headwinds (war, fuel costs, geopolitics). Deflected on cash deployment to index investing. Overall: firm but defensive, signaling internal concern about near-term deceleration.
Europe M&A and organic growth — Ahmed Madha, Unifi Capital
AnsweredQliniQ effective April 1, ₹44 Cr Q1 revenue. Full year expect ₹150-175 Cr from QliniQ. Overall Europe ₹180 Cr target. Organic ex-QliniQ grew 53.1% YoY.
Gross margin sustainability — Ahmed Madha, Unifi Capital
AnsweredFluid situation. Sitting on good inventory but war/freight/raw material costs offset gains. War ends → normalizes fast. Sustainable is 55-56%. Some inventory remains.
FY27 guidance maintenance — Meet Bhuva, Integrity Ventures
AnsweredNo, will stick with plan due to geopolitical volatility and uncertainties. Stand by historical projection.
Europe growth sustainability — Meet Bhuva, Integrity Ventures
PartialWill be able to sustain it.
Ireland and Germany ramp timeline — Meet Bhuva, Integrity Ventures
AnsweredGermany early Q3, better revenue expected. Ireland takes time (licenses needed), hopeful next fiscal year, not this year.
Consumer healthcare vision — Mihir Damania, Fident AMC
PartialExpanding OTC portfolio and brands. Lot of work, will invest resources, confident in direction but vague on specifics.
USFDA inspection timing — Mihir Damania, Fident AMC
AnsweredNo definite timeline. Can come any moment. One plant audited <12 months back. Depends on filings.
Q2/Q3 seasonality — Deepesh Sancheti, Manya Finance
AnsweredYes. From revenue standpoint, Q2 better than Q1, Q3 probably strongest. Will hit expected EBITDA margins.
Europe acquisition strategy — Deepesh Sancheti, Manya Finance
AnsweredTwo acquisitions done (Netherlands, Germany). Good launching pad. Grew very well on past acquisitions. Will need more acquisitions. Have corpus for inorganic strategies. M&A unpredictable.
US tariff strategy — Deepesh Sancheti, Manya Finance
DodgedPossibility always exists but don't put weightage on statements—change within days. Two years long; things may change with elections. Will watch and see.
Gross margin push higher — Vishal Manchanda, Systematix Group
AnsweredNo, unrealistic. 55-56% range more comfortable given geopolitical scenarios, war, crude, transportation.
India manufacturing proportion — Vishal Manchanda, Systematix Group
Answered65-70%, 70% higher side. From India.
Backward integration — Vishal Manchanda, Systematix Group
AnsweredNot pursuing actively. Developed some IPs on DMFs, exploring CRAMS module, but not active given macro.
Geography outlook — Vishal Manchanda, Systematix Group
PartialUnlike last year, all markets and geographies will do fairly well. Each subsidiary will contribute.
Cash allocation and ROC drag — Abhi Jain, AJ Capital
AnsweredNo, don't take that risk. Main aim is inorganic strategies to grow revenue. Acquisitions return faster than instruments. Averse to risk beyond control.
EBITDA margin progression — Abhi Jain, AJ Capital
PartialEnd of year 21-22% EBITDA is achievable.
Europe organic growth ex-QliniQ — Anand Moore, OM Advisors
AnsweredUK growth all organic, no inorganic in UK. QliniQ is revenue (not cash received). UK organic grew >50% YoY.
Europe 3-5 year outlook — Anand Moore, OM Advisors
AnsweredEurope cluster of many countries, present in two. Plan to expand, mostly via acquisitions. Within 5 years, Europe can do ₹1,000 Cr.
Goa unit 2 progress — Anand Moore, OM Advisors
AnsweredProgressing well. Projected ₹80 Cr revenue. Currently at ₹50+ Cr, so 60-65% utilization.
Manufacturing capacity and new plants — Aejas Lakhani, Unifi AMC
PartialLooking at couple targets. Too early. Have 1-2 years to work on objective. May need another plant in India. Nothing concrete. Need to get right price.
US OTC vs Rx mix — Nitin Agarwal, DAM Capital
AnsweredUK equally split: 55% Rx, 45% OTC. Europe tilting Rx: 80-85% Rx, 15% OTC (prescription market).
US market outlook 5-year — Nitin Agarwal, DAM Capital
AnsweredNo longer talking $200 Mn, working towards $300 Mn next, then $400 Mn if 5-year horizon. Immediate objective $300 Mn.
R&D focus areas — Nitin Agarwal, DAM Capital
AnsweredFocusing on product development, different delivery forms (more expensive). Doubling portfolio in every country in 2-3 years. Better resources as company grows larger.
US OTC competition dynamics — Nitin Agarwal, DAM Capital
AnsweredDon't see much change. See struggles from war/geopolitical scenarios, fuel prices, consumer affordability. Don't see competition changing. Some big players struggling (good news).
Cash reserve deployment — Jugal Shah, Individual Investor
PartialAnything possible. Smaller markets explore strategies; India acquisition means bigger valuation. ₹200-400 Cr could go to single deal. Money fuels growth. Year for inorganic strategy.
FY27 growth guidance conservatism — Jugal Shah, Individual Investor
PartialIn last call, spoke of doubling revenue (3-5 years). How many companies talk of doubling? From ₹3,000 Cr, doubling within 5 years is visibility. Still working towards it.
Guidance
FY27 top-line growth 15-20%
MediumReaffirmed despite 35.6% Q1 growth. Management cited geopolitical volatility and macro uncertainty as reasons for conservatism.
FY27 EBITDA margin 20-21% sustainable; 21-22% achievable by year-end
MediumCurrent 25.3% driven by favorable mix, inventory, FX (all temporary). 55-56% gross margin sustainable. Some pressure expected QoQ.
New manufacturing unit in India to be evaluated over 1-2 year horizon
LowNeeded for 3-5 year doubling target. Nothing concrete; targeting 'right price'. Goa unit 2 at 60-65% utilization.
Risks the call surfaced
Gross margin sustainability
HighCurrent 59.1% margin driven by low-cost inventory depletion (ending), favorable FX, and product mix. Management guides 55-56% sustainable, implying 300-400 bps compression risk if drivers reverse mid-year.
Guidance delivery gap
MediumQ1 grew 35.6% YoY but FY27 guidance is only 15-20% growth, implying sharp deceleration in H2. If current momentum sustains (as early indicators suggest), guidance will be massively beaten and credibility questioned.
Europe acquisition integration
MediumQliniQ and ABCnow acquisitions just completed. Integration execution risk (synergies, cultural, operational). Ireland entity needs licensing (wholesale, distribution, product); revenue not expected until FY28.
USFDA regulatory compliance
MediumThree USFDA-compliant plants globally. Inspection timing unpredictable; one facility audited <12 months back. Large US revenue exposure (45%) creates dependency on regulatory clearance.
Macro headwinds and geopolitics
MediumWar-related freight inflation, raw material cost pressure, consumer affordability concerns (fuel prices), and geopolitical uncertainty cited as reasons for cautious FY27 guidance. Non-Western markets (Rest of World) explicitly struggling.
Management
Score 7/10. Clear on strategy and numbers. Transparent on headwinds (gross margin sustainability, macro risks). Avoided upgrading guidance despite beat, signaling integrity. Some deflection on capital allocation philosophy (index investing). Strong track record on acquisitions (Netherlands, now Germany in progress). Grew from ₹3,000 Cr (implied prior) to ₹3,364 Cr run-rate in one year. Europe expansion on schedule; new geographies (Canada, Ireland, Germany) underway.
1 · Q2 FY27
Germany entity (ABCnow) revenue ramp; Q2 expected stronger than Q1 per management
2 · Q3 FY27
Management calls Q3 'strongest' quarter; Ireland entity expected to begin revenue generation
3 · FY28
₹4,000 crore revenue target (currently on 3,364 Cr run-rate from Q1); European expansion to ₹180 Cr full-year
Key risk: whether Q2-Q4 growth moderates sharply or current momentum sustains; current guidance implies significant deceleration.